Project Grant DP2CA281401
Award Date
9/20/22
Completion Date
8/31/25
Dollars Obligated
$3M
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Cancer Institute
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) provides $3,834,112 to develop and refine computational tools to advance the safety and efficacy of genome editing. The key products and services to be delivered include: Enhancing the CRISPRME tool to better predict off-target effects of genome editing across diverse human genomes. A new tool, CRISPRUS, will also be developed to leverage variation graphs, complete genomes,...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to improve the efficiency of CRISPR gene editing in human pluripotent stem cells. The goal is to develop a novel carbon nanotube array technology that can efficiently transfer nucleic acids and proteins into these cells to enhance CRISPR-based gene editing and homology-directed recombination. The $275,045 award to Advanced Gene...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $100,000 will support research to develop next-generation clustered regularly interspaced short palindromic repeat (CRISPR) systems for curing inherited diseases. Specifically, the awardee, the University of California, Berkeley, will work to circumvent in vivo delivery challenges with CRISPR-Cas9 by developing miniature RNA-guided genome editors smaller than Cas9 that can be...
The National Institute of General Medical Sciences (NIGMS) awarded a 3-year, $360,100 Project Grant under CFDA 93.859 (Biomedical Research and Research Training) to The Regents of the University of California, Berkeley (UC Berkeley) to develop precision base editing enzymes capable of correcting disease-causing point mutations in the genomes of hematopoietic stem and progenitor cells (HSPCs). The project aims to expand the scope of diseases amenable to CRISPR-mediated genetic correction by...
The U.S. Department of Health and Human Services' National Institute of General Medical Sciences (NIGMS) awarded a $1,638,033 project grant under CFDA 93.859 (Biomedical Research and Research Training) to the Scripps Research Institute in La Jolla, California. The grant supports the development of a CRISPR-free mammalian recombineering system that enables large-scale DNA insertions, deletions, and substitutions in mammalian cells without the need for cytotoxic double-strand breaks. The project...
The National Human Genome Research Institute (NHGRI) awarded a $1,375,594 Project Grant (CFDA 93.172 - Human Genome Research) to The Broad Institute, Inc. to develop a novel technology called Helicase-Assisted Continuous Evolution (HACE). HACE utilizes a helicase-deaminase fusion directed by a Cas9 nickase to perform targeted, long-range mutagenesis within the mammalian genome. This platform will enable the functional characterization of both non-coding regulatory elements and gene pathways...
This Project Grant award, with a total funding amount of $249,000.00, was provided by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), under the Human Genome Research Federal Grant Program (CFDA 93.172). The grant aims to conduct a multi-omic dissection of clonal hematopoiesis-associated diseases, with a focus on understanding the molecular mechanisms by which clonal hematopoiesis of indeterminate potential (CHIP) promotes various...
This $1,000,000.00 Project Grant awarded by the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) supports research to characterize the molecular mechanisms by which the bridge helix (BH) region of the CRISPR-associated (Cas) 9 and Cas12a enzymes contributes to DNA cleavage fidelity. The overarching goal is to develop error-proof variants of these genome editing tools that minimize unintended off-target DNA modifications. The award includes a sub-grant to the University...
The federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,507,500 to the University of Massachusetts Medical School (UMass Medical) to expand the capabilities of third-generation DNA/RNA sequencing technologies. The project aims to generate rapid and cost-effective training libraries to allow for direct detection of common DNA damage and RNA modifications, enabling innovative...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $222,904 to Harvard Medical School for research and development of programmable human artificial chromosomes (HACs) for cell-based therapies and screening applications. The key goals are to: 1) engineer HACs that can precisely control the expression of multiple...